<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">GAN</journal-id>
<journal-id journal-id-type="hwp">spgan</journal-id>
<journal-title>Genes &amp; Cancer</journal-title>
<issn pub-type="ppub">1947-6019</issn>
<issn pub-type="epub">1947-6027</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1947601912473604</article-id>
<article-id pub-id-type="publisher-id">10.1177_1947601912473604</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Short Reports</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Compound <italic>In Vivo</italic> Inactivation of <italic>Pml</italic> and <italic>p53</italic> Uncovers a Functional Interaction in Angiosarcoma Suppression</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Papa</surname><given-names>Antonella</given-names></name>
<xref ref-type="aff" rid="aff1-1947601912473604">1</xref>
<xref ref-type="aff" rid="aff2-1947601912473604">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Cordon-Cardo</surname><given-names>Carlos</given-names></name>
<xref ref-type="aff" rid="aff1-1947601912473604">1</xref>
<xref ref-type="aff" rid="aff3-1947601912473604">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Bernardi</surname><given-names>Rosa</given-names></name>
<xref ref-type="aff" rid="aff1-1947601912473604">1</xref>
<xref ref-type="aff" rid="aff2-1947601912473604">2</xref>
<xref ref-type="aff" rid="aff4-1947601912473604">4</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Pandolfi</surname><given-names>Pier Paolo</given-names></name>
<xref ref-type="aff" rid="aff1-1947601912473604">1</xref>
<xref ref-type="aff" rid="aff2-1947601912473604">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-1947601912473604"><label>1</label>Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA</aff>
<aff id="aff2-1947601912473604"><label>2</label>Cancer Biology and Genetics Program, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, NY, USA</aff>
<aff id="aff3-1947601912473604"><label>3</label>Department of Pathology, Mount Sinai Medical School, New York, NY, USA</aff>
<aff id="aff4-1947601912473604"><label>4</label>Division of Molecular Oncology, San Raffaele Scientific Institute, Milan, Italy</aff>
<author-notes>
<corresp id="corresp1-1947601912473604">Pier Paolo Pandolfi, Beth Israel Deaconess Cancer Center, CLS Building, Room 401, 330 Brookline Ave, Boston, MA 02215 (Email: <email>ppandolf@bidmc.harvard.edu</email>)</corresp>
<corresp id="corresp2-1947601912473604">Rosa Bernardi, San Raffaele Scientific Institute, via Olgettina, 60, Milan, 20132, Italy (Email: <email>bernardi.rosa@hsr.it</email>)</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>9</month>
<year>2012</year>
</pub-date>
<volume>3</volume>
<issue>9-10</issue>
<fpage>599</fpage>
<lpage>603</lpage>
<history>
<date date-type="received">
<day>2</day>
<month>10</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>9</day>
<month>12</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>The promyelocytic leukemia (<italic>PML</italic>) tumor suppressor gene was initially identified as part of the t(15:17) chromosomal translocation associated with acute promyelocytic leukemia (APL). The PML protein is responsible for the assembly and function of characteristic nuclear domains known as PML-nuclear bodies (PML-NBs), which have been implicated in a variety of cellular functions, including growth suppression, apoptosis, and cellular senescence. PML’s many roles have been linked, at least in part, to its functional interaction with the tumor suppressor p53. It has been shown that PML favors both p53 accumulation and transcriptional activity; in turn, PML expression is directly regulated by p53, and this reciprocal regulation contributes to p53-mediated apoptosis and senescence. Nevertheless, genetic proof and <italic>in vivo</italic> assessment of the relevance of this functional crosstalk are still missing. Here we show that complete <italic>Pml</italic> inactivation, in a context of <italic>p53</italic> heterozygosity, redistributes and expands the tumor spectrum leading to the formation of angiosarcomas and increased lymphomagenesis. Importantly, we find that <italic>Pml</italic> inactivation decreases the rate of loss of heterozygosity (LOH) in the remaining <italic>p53</italic> allele, revealing the relevancy of p53 haploinsufficiency to tumorigenesis. Our results thus lend <italic>in vivo</italic> genetic support to the importance of the crosstalk between these two critical tumor suppressor genes.</p>
</abstract>
<kwd-group>
<kwd>Pml</kwd>
<kwd>p53</kwd>
<kwd>angiosarcoma</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>September/October 2012</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="section1-1947601912473604" sec-type="intro">
<title>Introduction</title>
<p><italic>PML</italic> is a pleiotropic tumor suppressor gene involved in the regulation of a variety of biological processes ranging from regulation of apoptosis, stress response, and senescence to inhibition of neoangiogenesis.<sup><xref ref-type="bibr" rid="bibr1-1947601912473604">1</xref>,<xref ref-type="bibr" rid="bibr2-1947601912473604">2</xref></sup> The tumor suppressive function of PML was at first related to its role in the regulation of myeloid differentiation and the suppression of leukemogenesis.<sup><xref ref-type="bibr" rid="bibr2-1947601912473604">2</xref></sup> However, subsequent studies have revealed that PML regulates multiple tumor-suppressive pathways that restrain tumorigenesis in tissues of various histological origins. Accordingly, PML expression is lost in a large set of human solid cancers.<sup><xref ref-type="bibr" rid="bibr3-1947601912473604">3</xref></sup></p>
<p>It has long been known that in mice, deletion of <italic>Pml</italic> leads to impaired apoptotic response and the development of hematopoietic malignancies upon exposure to radiation or chemical carcinogens.<sup><xref ref-type="bibr" rid="bibr4-1947601912473604">4</xref></sup></p>
<p>More recently, inactivation of <italic>Pml</italic> in a <italic>Pten</italic> heterozygous background has been found to promote earlier onset and accelerated progression of colon and prostate cancer, in turn unveiling a new physiological role for Pml as a negative regulator of the proto-oncogene Akt.<sup><xref ref-type="bibr" rid="bibr5-1947601912473604">5</xref></sup> The modulatory effect of Pml on activation of the Akt signaling pathway occurs at 2 distinct levels: in addition to favoring direct Akt inhibition, Pml opposes mTOR activation in conditions of low oxygen concentrations, thus inhibiting HIF-1α synthesis and neoangiogenesis.<sup><xref ref-type="bibr" rid="bibr6-1947601912473604">6</xref></sup> These findings have been further corroborated in studies of the compound <italic>in vivo</italic> inactivation of <italic>Pml</italic> and <italic>Tsc2</italic>, a direct negative regulator of mTOR. We have found that kidney tumorigenesis originating in <italic>Tsc2</italic> heterozygous mice was accelerated by <italic>Pml</italic> loss through mTOR up-regulation.<sup><xref ref-type="bibr" rid="bibr7-1947601912473604">7</xref></sup></p>
<p>Functionally, PML is the key component of nuclear macromolecular structures known as PML nuclear bodies (PML-NBs). In these structures, PML orchestrates a dynamic network of protein-protein interactions that define the PML-NBs as functional hubs for the regulation of diverse biochemical processes. Among the best characterized and most studied functional interactors of PML is the tumor suppressor p53.<sup><xref ref-type="bibr" rid="bibr1-1947601912473604">1</xref>,<xref ref-type="bibr" rid="bibr2-1947601912473604">2</xref></sup></p>
<p><italic>p53</italic> is one of the most often mutated genes in human cancer, owing to its ability to regulate cell cycle checkpoints, apoptosis, and senescence. Mice suffering complete loss of <italic>p53</italic> are viable and die mainly of thymic lymphoma by 9 months of age.<sup><xref ref-type="bibr" rid="bibr8-1947601912473604">8</xref>,<xref ref-type="bibr" rid="bibr9-1947601912473604">9</xref></sup> By contrast, <italic>p53</italic> heterozygous mice develop various types of sarcoma, and progression to cancer is invariably achieved through loss of function of the wild-type allele (loss of heterozygosity or selection for mutations).<sup><xref ref-type="bibr" rid="bibr8-1947601912473604">8</xref></sup> p53 acts as a transcription factor whose activity is regulated by complex posttranslational modifications. Acetylation, phosphorylation, and ubiquitination of p53 have all been found to occur in the PML-NBs, and PML regulates these events to favor p53 stabilization and activation.<sup><xref ref-type="bibr" rid="bibr1-1947601912473604">1</xref>,<xref ref-type="bibr" rid="bibr2-1947601912473604">2</xref></sup> For example, PML promotes p53 acetylation and favors p53-induced senescence or apoptosis upon Ras hyperactivation and DNA damage.<sup><xref ref-type="bibr" rid="bibr10-1947601912473604">10</xref><xref ref-type="bibr" rid="bibr11-1947601912473604"/>-<xref ref-type="bibr" rid="bibr12-1947601912473604">12</xref></sup> Also, PML regulates p53 stability through regulation of p53-Mdm2 interaction. Thus, in the NBs, PML promotes p53 modifications that protect it from Mdm2-mediated ubiquitination,<sup><xref ref-type="bibr" rid="bibr13-1947601912473604">13</xref><xref ref-type="bibr" rid="bibr14-1947601912473604"/>-<xref ref-type="bibr" rid="bibr15-1947601912473604">15</xref></sup> whereas in the nucleolus, PML sequesters Mdm2 to prevent p53 ubiquitination and degradation upon DNA damage.<sup><xref ref-type="bibr" rid="bibr16-1947601912473604">16</xref></sup></p>
<p>In addition to the regulatory network orchestrated by PML to induce p53 tumor suppressive functions, PML itself is a direct transcriptional p53 target upon expression of oncogenic Ras,<sup><xref ref-type="bibr" rid="bibr11-1947601912473604">11</xref></sup> which generates a positive feedback loop that reinforces p53 responses to promote apoptosis and senescence.</p>
<p>The characterization of the PML-p53 regulatory axis has been achieved through a number of elegant <italic>in vitro</italic> studies, but genetic proof of their functional interaction and its relevance <italic>in vivo</italic> are still missing. To define the relative contribution of Pml to p53 functions and their possible crosstalk, we performed an <italic>in vivo</italic> analysis of <italic>p53/Pml</italic> compound mutant mice and found that loss of <italic>Pml</italic> affects tumorigenesis induced by <italic>p53</italic> haploinsufficiency by modifying the tumor spectrum and lowering the genetic pressure for complete <italic>p53</italic> loss.</p>
</sec>
<sec id="section2-1947601912473604" sec-type="results|discussion">
<title>Results and Discussion</title>
<p>To gain insights into the functional interconnection between Pml and p53, we crossed <italic>p53</italic> heterozygous mice with mice heterozygous for <italic>Pml</italic> in order to generate <italic>p53</italic> heterozygous mutants with decreasing <italic>Pml</italic> dosage: <italic>p53<sup>+/−</sup> Pml<sup>+/+</sup>, p53<sup>+/−</sup> Pml<sup>+/−</sup></italic>, and <italic>p53<sup>+/−</sup> Pml<sup>−/−</sup></italic> mice. Because PML has been described as a critical regulator of p53 functions <italic>in vitro</italic>,<sup><xref ref-type="bibr" rid="bibr10-1947601912473604">10</xref><xref ref-type="bibr" rid="bibr11-1947601912473604"/>-<xref ref-type="bibr" rid="bibr12-1947601912473604">12</xref></sup> we hypothesized that reduced <italic>Pml</italic> expression would result in decreased p53 functional output and therefore more pronounced tumorigenesis. To test our hypothesis, we performed a histopathological analysis of tumor tissues from male and female <italic>p53<sup>+/−</sup></italic> mice with decreasing levels of <italic>Pml</italic> at time of death. As expected, all <italic>p53<sup>+/−</sup></italic> mice of a mixed 129/Sv-C57BL/6 genetic background with wild-type expression of <italic>Pml</italic> developed sarcomas with a predominance of osteosarcomas (50% of all tumors, <italic>n</italic> = 11). Fewer mice also developed fibrosarcomas (27.3%, <italic>n</italic> = 6) and squamous cell carcinomas (22.7%, <italic>n</italic> = 5) (<xref ref-type="fig" rid="fig1-1947601912473604">Fig. 1A</xref>). A 50% reduction in <italic>Pml</italic> expression levels in littermate animals of the same genetic background did not greatly modify tumor distribution driven by heterozygous loss of <italic>p53</italic>: as shown in <xref ref-type="fig" rid="fig1-1947601912473604">Fig. 1</xref>, <xref ref-type="fig" rid="fig1-1947601912473604">B</xref> and <xref ref-type="fig" rid="fig1-1947601912473604">C</xref>, the majority of <italic>p53<sup>+/−</sup> Pml<sup>+/−</sup></italic> mice developed aggressive sarcomas, and the most representative tumor type was again osteosarcoma (60%; <italic>n</italic> = 9), followed by fibrosarcoma (20%; <italic>n</italic> = 3). In addition, however, we found that a small percentage of <italic>p53<sup>+/−</sup> Pml<sup>+/−</sup></italic> mice developed angiosarcoma (7%, <italic>n</italic> = 1) and lymphomas (13%, <italic>n</italic> = 2), which were not observed in the <italic>Pml</italic> wild-type context.</p>
<fig id="fig1-1947601912473604" position="float">
<label>Figure 1.</label>
<caption>
<p>Histopathological analysis of the tumor spectrum observed in the indicated cohorts of mice. <bold>(A)</bold> and <bold>(B)</bold> Tumor type distribution in <italic>p53<sup>+/−</sup> Pml<sup>+/+</sup></italic> and <italic>p53<sup>+/−</sup> Pml<sup>+/−</sup></italic> mutant mice. The 2 cohorts of mice display a similar tumor spectrum, with osteosarcoma being the most common type of tumor—50% of incidence in <italic>p53<sup>+/−</sup> Pml<sup>+/+</sup></italic> (<italic>n</italic> = 11) and 60% in <italic>p53<sup>+/−</sup> Pml<sup>+/−</sup></italic> mice (<italic>n</italic> = 9)—followed by fibrosarcoma, 27% (<italic>n</italic> = 6) and 20% (<italic>n</italic> = 3), respectively. A small percentage of <italic>p53<sup>+/−</sup> Pml<sup>+/−</sup></italic> mice also developed angiosarcoma (7%, <italic>n</italic> = 1) and lymphoma (13%, <italic>n</italic> = 2). <bold>(C)</bold> Representative H&amp;E staining of osteosarcoma tumor commonly found in <italic>p53<sup>+/−</sup> Pml<sup>+/+</sup></italic> and <italic>p53<sup>+/−</sup> Pml<sup>+/−</sup></italic> mice. <bold>(D)</bold> <italic>p53<sup>+/−</sup> Pml<sup>−/−</sup></italic> mutant mice develop a wider range of tumor types, with angiosarcoma being the most prominent tumor (29.7%, <italic>n</italic> = 11), followed by osteosarcoma (24.3%, <italic>n</italic> = 9), lymphoma (19%, <italic>n</italic> = 7), squamous cell carcinoma (10.8%, <italic>n</italic> = 4), and fibrosarcoma (5.4%, <italic>n</italic> = 2). 10.8% of mice (<italic>n</italic> = 4) also developed more rare types of sarcoma. <bold>(E)</bold> Representative H&amp;E staining of angiosarcoma found in <italic>p53<sup>+/−</sup> Pml<sup>−/−</sup></italic> mutant mice.</p>
</caption>
<graphic xlink:href="10.1177_1947601912473604-fig1.tif"/></fig>
<p>When we analyzed the tumor burden of <italic>p53<sup>+/−</sup></italic> mice with complete loss of <italic>Pml</italic> compared with <italic>p53<sup>+/−</sup></italic> mice retaining <italic>Pml</italic> expression, we found a significant variation in tumor type distribution, mainly due to the high frequency of angiosarcomas (<italic>P</italic> = 0.04; <xref ref-type="fig" rid="fig1-1947601912473604">Fig. 1D</xref>) and lymphomas (<italic>P</italic> = 0.03; <xref ref-type="fig" rid="fig1-1947601912473604">Fig. 1E</xref>), which were never found in littermate <italic>p53<sup>+/−</sup></italic> mice of comparable genetic background. Indeed, 11 of 37 (29.7%) <italic>p53<sup>+/−</sup> Pml<sup>−/−</sup></italic> mice developed angiosarcomas, and 7 of 37 developed lymphomas (19%). Angiosarcomas appeared to arise at the expense of osteosarcomas and fibrosarcomas, which were reduced from about 50% in <italic>p53<sup>+/−</sup></italic> mice to 24.3% in <italic>p53<sup>+/−</sup> Pml<sup>−/−</sup></italic> mice (<italic>P</italic> = 0.045) and from 27% to about 5% (<italic>P</italic> = 0.017), respectively. A lower number of mice developed squamous cell carcinomas (10.8%, <italic>n</italic> = 4) and more rare types of sarcoma (10.8%, <xref ref-type="fig" rid="fig1-1947601912473604">Fig. 1D</xref>). Angiosarcoma is a malignant mesenchymal tumor that arises from cells lining the walls of blood vessels: It is formed by highly proliferating endothelial cells and is rich in blood. We found mainly subcutaneous angiosarcomas developing on the head and neck area as well as the backs of the mice. In addition, 1 of 5 <italic>p53<sup>+/−</sup> Pml<sup>−/−</sup></italic> mice developed lymphoma, a malignancy commonly found in <italic>p53</italic> null mice, indicating that loss of <italic>Pml</italic> may modify tumorigenesis driven by <italic>p53</italic> heterozygosity toward a phenotype normally observed upon complete <italic>p53</italic> loss. Indeed, mice that completely lacked <italic>p53</italic> expression died mainly of lymphoma by 9 months of age in the mixed 129/Sv-C57BL/6 genetic background in which we bred our mice, and loss of <italic>Pml</italic> did not worsen lymphomagenesis, nor did it lead to earlier sarcomagenesis or variation in the tumor-type compared with <italic>p53</italic> null mice (data not shown). Although loss of <italic>Pml</italic> modified <italic>p53</italic>-driven tumorigenesis toward more malignant phenotypes, we found that the life span of <italic>p53<sup>+/−</sup></italic> mice was not affected by reduced <italic>Pml</italic> levels (<xref ref-type="fig" rid="fig2-1947601912473604">Fig. 2A</xref>). Also, we performed a parallel analysis of the life span of <italic>p53<sup>−/−</sup></italic> with <italic>Pml</italic><sup>−/−</sup> mice, and even in this setting we found no difference in overall survival (<xref ref-type="fig" rid="fig2-1947601912473604">Fig. 2B</xref>).</p>
<fig id="fig2-1947601912473604" position="float">
<label>Figure 2.</label>
<caption>
<p>Survival analysis upon <italic>Pml</italic> and <italic>p53</italic> inactivation. Kaplan-Meier graphs showing cumulative survival curves in <italic>p53</italic> heterozygous mice <bold>(A)</bold> and <italic>p53</italic> null mice <bold>(B)</bold> combined with the indicated <italic>Pml</italic> genotypes. No difference was observed among the lines.</p>
</caption>
<graphic xlink:href="10.1177_1947601912473604-fig2.tif"/></fig>
<p>Critically, because tumorigenesis in <italic>p53</italic> heterozygous mice is frequently accompanied by loss of the <italic>p53</italic> wild-type genomic locus (loss of heterozygosity, LOH),<sup><xref ref-type="bibr" rid="bibr8-1947601912473604">8</xref>,<xref ref-type="bibr" rid="bibr17-1947601912473604">17</xref></sup> we sought to determine whether loss of <italic>Pml</italic> expression impacted the LOH of the remaining <italic>p53</italic> allele. To this end, we performed Southern blot analyses on DNA derived from paired tail and tumor tissues, from a number of mice with different genotypes. Our results showed that although <italic>p53<sup>+/−</sup> Pml<sup>+/+</sup></italic> and <italic>p53<sup>+/−</sup> Pml<sup>+/−</sup></italic> tumors in the late stage of tumorigenesis were characterized by 80% loss of the wild-type <italic>p53</italic> allele, in samples from <italic>p53<sup>+/−</sup> Pml<sup>−/−</sup></italic> mice 50% of tumors retained expression of the <italic>p53</italic> locus (<xref ref-type="fig" rid="fig3-1947601912473604">Fig. 3</xref>, <xref ref-type="fig" rid="fig3-1947601912473604">A</xref> and <xref ref-type="fig" rid="fig3-1947601912473604">B</xref>).</p>
<fig id="fig3-1947601912473604" position="float">
<label>Figure 3.</label>
<caption>
<p>Analysis of <italic>p53</italic> Loss of heterozygosity (LOH) on tumor tissues DNA derived from the indicated cohorts of mice. <bold>(A)</bold> Representative Southern blot performed to evaluate the status of <italic>p53</italic> during late stages of tumorigenesis. <bold>(B)</bold> Frequency of <italic>p53</italic> LOH observed in compound mutant mice. Loss of <italic>Pml</italic> reduces the percentage of LOH at the <italic>p53</italic> locus. <bold>(C)</bold> Schematic representation of the genetics sustaining tumor progression. <italic>p53</italic> heterozygosity leads to sarcoma development. LOH at the <italic>p53</italic> locus is a common marker for cancer development. <italic>Pml</italic> loss in a <italic>p53</italic> heterozygous background mimics loss of <italic>p53</italic> functions, thus reducing the selective pressure at the <italic>p53</italic> locus and lowering the percentage of LOH.</p>
</caption>
<graphic xlink:href="10.1177_1947601912473604-fig3.tif"/></fig>
<p>Taken together, these results allow us to reach important conclusions on the relevance of the Pml-p53-regulated tumorigenesis <italic>in vivo</italic>.</p>
<p>First, we did not find significant differences in the overall survival rates of <italic>p53<sup>+/−</sup></italic> and <italic>p53<sup>+/−</sup> Pml<sup>−/−</sup></italic> mutant mice, but we found profound differences in tumor spectrum in the absence of <italic>Pml</italic>. These findings are in stark contrast to what we have previously observed upon crossing <italic>Pml<sup>−/−</sup></italic> mice with <italic>Tsc2<sup>+/−</sup></italic> mice<sup><xref ref-type="bibr" rid="bibr7-1947601912473604">7</xref></sup>: Although in the context of <italic>Tsc2</italic>-driven tumorigenesis, loss of <italic>Pml</italic> affects tumor aggressiveness in the kidney epithelium by favoring mTOR hyperactivation and tumor acceleration, in a context of prevalent sarcomagenesis driven by <italic>p53</italic> inactivation, loss of <italic>Pml</italic> prevalently modifies tumor identity. In this respect, we observed that loss of <italic>Pml</italic> caused 2 main phenotypes: a shift from osteo/fibrosarcomas to angiosarcomas, and the occurrence of lymphomas. As we had previously shown that PML regulates Hif1α levels and neo-angiogenesis in fibrosarcoma in hypoxic conditions,<sup><xref ref-type="bibr" rid="bibr6-1947601912473604">6</xref>,<xref ref-type="bibr" rid="bibr7-1947601912473604">7</xref></sup> we can now speculate that loss of <italic>Pml in vivo</italic> defines a transformative step favoring the development of vascularized tumors in the context of a preexisting insult such as <italic>p53</italic> heterozygosity (<xref ref-type="fig" rid="fig3-1947601912473604">Fig. 3C</xref>). Second, we found the appearance of lymphomas in a small percentage of <italic>p53<sup>+/−</sup> Pml<sup>+/−</sup></italic> mice, and more commonly in <italic>p53<sup>+/−</sup> Pml<sup>−/−</sup></italic> mice. Because lymphomas are typical of <italic>p53<sup>−/−</sup></italic> mice, we conclude that compound inactivation of <italic>p53</italic> and <italic>Pml</italic> in the thymus may functionally mimic total <italic>p53</italic> loss, thus promoting lymphomagenesis. Importantly, the fact that we also found lymphomas in <italic>p53<sup>+/−</sup> Pml<sup>+/−</sup></italic> mice, although at low penetrance, suggests that heterozygous inactivation of <italic>Pml</italic> may also decrease p53 activity, thus enhancing the consequences of p53 haploinsufficiency <italic>in vivo</italic>. In turn, these findings provide further support to the importance in tumorigenesis of partial functional losses and compound haploinsufficiency of tumor suppressor genes.<sup><xref ref-type="bibr" rid="bibr18-1947601912473604">18</xref></sup></p>
<p>Third, our analysis of <italic>p53</italic> levels during late stages of tumorigenesis revealed a reduction of <italic>p53</italic> LOH in the absence of <italic>Pml</italic>. In line with the lymphomagenesis data, the LOH analysis further suggests that the tumor suppressive role of p53 is strongly linked to Pml expression and that <italic>Pml</italic> loss causes a functional impairment to p53, thus mimicking <italic>p53</italic> LOH (<xref ref-type="fig" rid="fig3-1947601912473604">Fig. 3C</xref>). Although we have not performed a sequencing analysis to verify the occurrence of point mutations in the remaining <italic>p53</italic> allele, we propose to exclude this possibility for 2 reasons: (1) it is widely accepted that point mutations in <italic>p53</italic> may generate dominant negative/gain-of-function effects, thus leading to increased metastatic potential and invasiveness,<sup><xref ref-type="bibr" rid="bibr17-1947601912473604">17</xref></sup> none of which was found in our mice; and (2) p53 mutations may lead to appearance of carcinomas rather than sarcomas<sup><xref ref-type="bibr" rid="bibr17-1947601912473604">17</xref></sup>; in our analysis however, we only identified sarcoma tumors.</p>
<p>Thus, our findings demonstrate <italic>in vivo</italic> the existence of a functional crosstalk between Pml and p53 and support a model in which their reciprocally balanced activities favor each other roles to coordinate tumor suppression.</p>
</sec>
<sec id="section3-1947601912473604" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="section4-1947601912473604">
<title>Mice</title>
<p><italic>Pml<sup>+/−</sup></italic> and <italic>p53<sup>+/−</sup></italic> mice used in this study were previously generated<sup><xref ref-type="bibr" rid="bibr4-1947601912473604">4</xref>,<xref ref-type="bibr" rid="bibr9-1947601912473604">9</xref></sup>. <italic>Pml<sup>+/−</sup></italic> mice were crossed with <italic>p53<sup>+/−</sup></italic> mice to generate all combinations of compound mutant mice. All mice were of mixed 129/Sv and C57BL/6 strains. Animals were sacrificed when moribund. All mice were cared for according to NIH-approved institutional animal care guidelines and upon approval by the Institutional Committee at the Memorial Sloan-Kettering Cancer Center, New York, NY.</p>
</sec>
<sec id="section5-1947601912473604">
<title>Histopathology</title>
<p>Normal and tumor tissue samples were fixed in 4% paraformaldehyde (PFA) for 48 hours at 4°C, washed twice with PBS 1×, and transferred to 70% ethanol. Samples were embedded in paraffin, and sections 4-5 mm of thickness were stained with H&amp;E according to standard protocols. <italic>P</italic> values were calculated by comparing the number of specific tumor types in mice <italic>p53<sup>+/−</sup> Pml<sup>−/−</sup></italic> versus mice <italic>p53<sup>+/−</sup> Pml<sup>+/+</sup></italic> with Student <italic>t</italic> test.</p>
</sec>
<sec id="section6-1947601912473604">
<title>Loss of heterozygosity (LOH) analysis</title>
<p>LOH of <italic>p53</italic> allele was performed by Southern blot analysis as previously published<sup><xref ref-type="bibr" rid="bibr9-1947601912473604">9</xref></sup>.</p>
</sec>
</sec>
</body>
<back>
<ack>
<p>The authors would like to thank all members of the Pandolfi laboratory, in particular Andrea Lunardi and Ming Chen for insightful comments and Thomas Garvey for editing the manuscript.</p>
</ack>
<fn-group>
<fn fn-type="conflict">
<label>Declaration of Conflicting Interests</label>
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the NIH/NCI grant (R01 CA-71692), awarded to P.P.P. A.P. was supported in part by the American-Italian Cancer Foundation Post-Doctoral Research Fellowship.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1947601912473604">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bernardi</surname><given-names>R</given-names></name>
<name><surname>Pandolfi</surname><given-names>PP</given-names></name>
</person-group>. <article-title>Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies</article-title>. <source>Nat Rev Mol Cell Biol</source>. <year>2007</year>;<volume>8</volume>(<issue>12</issue>):<fpage>1006</fpage>-<lpage>16</lpage>. Epub 2007 Oct 12.</citation>
</ref>
<ref id="bibr2-1947601912473604">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bernardi</surname><given-names>R</given-names></name>
<name><surname>Papa</surname><given-names>A</given-names></name>
<name><surname>Pandolfi</surname><given-names>PP</given-names></name>
</person-group>. <article-title>Regulation of apoptosis by PML and the PML-NBs</article-title>. <source>Oncogene</source>. <year>2008</year>;<volume>27</volume>(<issue>48</issue>):<fpage>6299</fpage>-<lpage>312</lpage>. Epub 2008 Oct 22.</citation>
</ref>
<ref id="bibr3-1947601912473604">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gurrieri</surname><given-names>C</given-names></name>
<name><surname>Capodieci</surname><given-names>P</given-names></name>
<name><surname>Bernardi</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Loss of the tumor suppressor PML in human cancers of multiple histologic origins</article-title>. <source>J Natl Cancer Inst</source>. <year>2004</year>;<volume>96</volume>(<issue>4</issue>):<fpage>269</fpage>-<lpage>79</lpage>. Epub 2004 Feb 19.</citation>
</ref>
<ref id="bibr4-1947601912473604">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>ZG</given-names></name>
<name><surname>Delva</surname><given-names>L</given-names></name>
<name><surname>Gaboli</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Role of PML in cell growth and the retinoic acid pathway</article-title>. <source>Science</source>. <year>1998</year>;<volume>279</volume>(<issue>5356</issue>):<fpage>1547</fpage>-<lpage>51</lpage>. Epub 1998 Mar 21.</citation>
</ref>
<ref id="bibr5-1947601912473604">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Trotman</surname><given-names>LC</given-names></name>
<name><surname>Alimonti</surname><given-names>A</given-names></name>
<name><surname>Scaglioni</surname><given-names>PP</given-names></name>
<name><surname>Koutcher</surname><given-names>JA</given-names></name>
<name><surname>Cordon-Cardo</surname><given-names>C</given-names></name>
<name><surname>Pandolfi</surname><given-names>PP</given-names></name>
</person-group>. <article-title>Identification of a tumour suppressor network opposing nuclear Akt function</article-title>. <source>Nature</source>. <year>2006</year>;<volume>441</volume>(<issue>7092</issue>):<fpage>523</fpage>-<lpage>7</lpage>. Epub 2006 May 09.</citation>
</ref>
<ref id="bibr6-1947601912473604">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bernardi</surname><given-names>R</given-names></name>
<name><surname>Guernah</surname><given-names>I</given-names></name>
<name><surname>Jin</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR</article-title>. <source>Nature</source>. <year>2006</year>;<volume>442</volume>(<issue>7104</issue>):<fpage>779</fpage>-<lpage>85</lpage>. Epub 2006 Aug 18.</citation>
</ref>
<ref id="bibr7-1947601912473604">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bernardi</surname><given-names>R</given-names></name>
<name><surname>Papa</surname><given-names>A</given-names></name>
<name><surname>Egia</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Pml represses tumour progression through inhibition of mTOR</article-title>. <source>EMBO Mol Med</source>. <year>2011</year>;<volume>3</volume>(<issue>5</issue>):<fpage>249</fpage>-<lpage>57</lpage>. Epub 2011 Mar 10.</citation>
</ref>
<ref id="bibr8-1947601912473604">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jacks</surname><given-names>T</given-names></name>
<name><surname>Remington</surname><given-names>L</given-names></name>
<name><surname>Williams</surname><given-names>BO</given-names></name>
<etal/>
</person-group>. <article-title>Tumor spectrum analysis in p53-mutant mice</article-title>. <source>Curr Biol</source>. <year>1994</year>;<volume>4</volume>(<issue>1</issue>):<fpage>1</fpage>-<lpage>7</lpage>. Epub 1994 Jan 01.</citation>
</ref>
<ref id="bibr9-1947601912473604">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Donehower</surname><given-names>LA</given-names></name>
<name><surname>Harvey</surname><given-names>M</given-names></name>
<name><surname>Slagle</surname><given-names>BL</given-names></name>
<etal/>
</person-group>. <article-title>Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours</article-title>. <source>Nature</source>. <year>1992</year>;<volume>356</volume>(<issue>6366</issue>):<fpage>215</fpage>-<lpage>21</lpage>. Epub 1992 Mar 29.</citation>
</ref>
<ref id="bibr10-1947601912473604">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pearson</surname><given-names>M</given-names></name>
<name><surname>Carbone</surname><given-names>R</given-names></name>
<name><surname>Sebastiani</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>PML regulates p53 acetylation and premature senescence induced by oncogenic Ras</article-title>. <source>Nature</source>. <year>2000</year>;<volume>406</volume>(<issue>6792</issue>):<fpage>207</fpage>-<lpage>10</lpage>. Epub 2000 Jul 26.</citation>
</ref>
<ref id="bibr11-1947601912473604">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>de Stanchina</surname><given-names>E</given-names></name>
<name><surname>Querido</surname><given-names>E</given-names></name>
<name><surname>Narita</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>PML is a direct p53 target that modulates p53 effector functions</article-title>. <source>Mol Cell</source>. <year>2004</year>;<volume>13</volume>(<issue>4</issue>):<fpage>523</fpage>-<lpage>35</lpage>. Epub 2004 Mar 03.</citation>
</ref>
<ref id="bibr12-1947601912473604">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guo</surname><given-names>A</given-names></name>
<name><surname>Salomoni</surname><given-names>P</given-names></name>
<name><surname>Luo</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>The function of PML in p53-dependent apoptosis</article-title>. <source>Nat Cell Biol</source>. <year>2000</year>;<volume>2</volume>(<issue>10</issue>):<fpage>730</fpage>-<lpage>6</lpage>. Epub 2000 Oct 12.</citation>
</ref>
<ref id="bibr13-1947601912473604">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ferbeyre</surname><given-names>G</given-names></name>
<name><surname>de Stanchina</surname><given-names>E</given-names></name>
<name><surname>Querido</surname><given-names>E</given-names></name>
<name><surname>Baptiste</surname><given-names>N</given-names></name>
<name><surname>Prives</surname><given-names>C</given-names></name>
<name><surname>Lowe</surname><given-names>SW</given-names></name>
</person-group>. <article-title>PML is induced by oncogenic ras and promotes premature senescence</article-title>. <source>Genes Dev</source>. <year>2000</year>;<volume>14</volume>(<issue>16</issue>):<fpage>2015</fpage>-<lpage>27</lpage>. Epub 2000 Aug 19.</citation>
</ref>
<ref id="bibr14-1947601912473604">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Louria-Hayon</surname><given-names>I</given-names></name>
<name><surname>Grossman</surname><given-names>T</given-names></name>
<name><surname>Sionov</surname><given-names>RV</given-names></name>
<name><surname>Alsheich</surname><given-names>O</given-names></name>
<name><surname>Pandolfi</surname><given-names>PP</given-names></name>
<name><surname>Haupt</surname><given-names>Y</given-names></name>
</person-group>. <article-title>The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation</article-title>. <source>J Biol Chem</source>. <year>2003</year>;<volume>278</volume>(<issue>35</issue>):<fpage>33134</fpage>-<lpage>41</lpage>. Epub 2003 Jun 18.</citation>
</ref>
<ref id="bibr15-1947601912473604">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alsheich-Bartok</surname><given-names>O</given-names></name>
<name><surname>Haupt</surname><given-names>S</given-names></name>
<name><surname>Alkalay-Snir</surname><given-names>I</given-names></name>
<name><surname>Saito</surname><given-names>S</given-names></name>
<name><surname>Appella</surname><given-names>E</given-names></name>
<name><surname>Haupt</surname><given-names>Y</given-names></name>
</person-group>. <article-title>PML enhances the regulation of p53 by CK1 in response to DNA damage</article-title>. <source>Oncogene</source>. <year>2008</year>;<volume>27</volume>(<issue>26</issue>):<fpage>3653</fpage>-<lpage>61</lpage>. Epub 2008 Feb 05.</citation>
</ref>
<ref id="bibr16-1947601912473604">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bernardi</surname><given-names>R</given-names></name>
<name><surname>Scaglioni</surname><given-names>PP</given-names></name>
<name><surname>Bergmann</surname><given-names>S</given-names></name>
<name><surname>Horn</surname><given-names>HF</given-names></name>
<name><surname>Vousden</surname><given-names>KH</given-names></name>
<name><surname>Pandolfi</surname><given-names>PP</given-names></name>
</person-group>. <article-title>PML regulates p53 stability by sequestering Mdm2 to the nucleolus</article-title>. <source>Nat Cell Biol</source>. <year>2004</year>;<volume>6</volume>(<issue>7</issue>):<fpage>665</fpage>-<lpage>72</lpage>. Epub 2004 Jun 15.</citation>
</ref>
<ref id="bibr17-1947601912473604">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cadwell</surname><given-names>C</given-names></name>
<name><surname>Zambetti</surname><given-names>GP</given-names></name>
</person-group>. <article-title>The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth</article-title>. <source>Gene</source>. <year>2001</year>;<volume>277</volume>(<issue>1-2</issue>):<fpage>15</fpage>-<lpage>30</lpage>. Epub 2001 Oct 17.</citation>
</ref>
<ref id="bibr18-1947601912473604">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Berger</surname><given-names>AH</given-names></name>
<name><surname>Knudson</surname><given-names>AG</given-names></name>
<name><surname>Pandolfi</surname><given-names>PP</given-names></name>
</person-group>. <article-title>A continuum model for tumour suppression</article-title>. <source>Nature</source>. <year>2011</year>;<volume>476</volume>(<issue>7359</issue>):<fpage>163</fpage>-<lpage>9</lpage>. Epub 2011 Aug 13.</citation>
</ref>
</ref-list>
</back>
</article>